Tag #Biosimilars

Showing 1 to 7 of 7 results

theglobeandmail.com

🌐 85% Global Worthiness

Sep 5, 01:18

Health Canada vows to expedite biosimilar drug approvals to reduce costs

Health Canada is addressing a backlog in biosimilar drug approvals, aiming to accelerate the market entry of cheaper alternatives to costly biologic drugs, driven by a 400 percent surge in submissions since 2016 and a need to reduce costs for public drug plans.

Health Canada vows to expedite biosimilar drug approvals to reduce costs

Health Canada is addressing a backlog in biosimilar drug approvals, aiming to accelerate the market entry of cheaper alternatives to costly biologic drugs, driven by a 400 percent surge in submissions since 2016 and a need to reduce costs for public drug plans.

Progress

20% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How are these delays impacting drugmakers and healthcare payers?

Delays threaten the financial viability of biosimilar drugmakers, potentially deterring future investments in Canada. Simultaneously, the delays force public drug plans to continue paying for more expensive brand-name biologics, increasing healthcare costs. The pan-Canadian Pharmaceutical Alliance, which negotiates drug prices, is impacted by the delayed approvals.

forbes.com

🌐 85% Global Worthiness

May 26, 13:11

Biocon's Biosimilar Strategy Disrupts Global Healthcare

Kiran Mazumdar-Shaw, thwarted in her brewing ambitions, founded Biocon, a $1.9 billion biopharmaceutical company producing cheaper biosimilar drugs, impacting global healthcare access and resulting in a $3.2 billion personal fortune.

Biocon's Biosimilar Strategy Disrupts Global Healthcare

Kiran Mazumdar-Shaw, thwarted in her brewing ambitions, founded Biocon, a $1.9 billion biopharmaceutical company producing cheaper biosimilar drugs, impacting global healthcare access and resulting in a $3.2 billion personal fortune.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the primary impact of Biocon's biosimilar strategy on global healthcare?

Kiran Mazumdar-Shaw, initially aiming to be a brewmaster, founded Biocon, a global biopharmaceutical company, after facing gender discrimination in the brewing industry. Biocon's success stems from producing cheaper biosimilars, significantly impacting healthcare costs globally. This innovative approach has resulted in a $1.9 billion revenue company and a $3.2 billion fortune for Mazumdar-Shaw.

forbes.com

🌐 85% Global Worthiness

Apr 6, 22:10

Senate Advances Six Bills to Reform Drug Patent System

The Senate Judiciary Committee advanced six bipartisan bills to reform the drug patent system, aiming to curb anti-competitive practices like "patent thickets" and "product hopping" that inflate drug prices; the legislation's success remains uncertain due to past failures.

Senate Advances Six Bills to Reform Drug Patent System

The Senate Judiciary Committee advanced six bipartisan bills to reform the drug patent system, aiming to curb anti-competitive practices like "patent thickets" and "product hopping" that inflate drug prices; the legislation's success remains uncertain due to past failures.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the main tactics used by pharmaceutical companies to extend monopolies on brand-name drugs, and how do the proposed bills aim to address these?

The bills target practices that allow drug manufacturers to extend their patent protection beyond the original timeframe, thus impeding the market entry of cheaper generic and biosimilar drugs. This has resulted in significantly higher prices for many brand-name drugs in the US compared to other countries. The legislation seeks to create a more competitive market, benefiting consumers.

jpost.com

🌐 75% Global Worthiness

Jan 30, 19:10

Teva Exceeds 2024 Expectations but 2025 Outlook Disappoints

Teva Pharmaceutical Industries reported exceeding 2024 financial results with $4.2 billion in Q4 revenue and $16.5 billion in full-year revenue; however, its share price fell almost 10% due to a less optimistic 2025 outlook of $16.8-17.4 billion in revenue and $2.35-2.65 non-GAAP EPS.

Teva Exceeds 2024 Expectations but 2025 Outlook Disappoints

Teva Pharmaceutical Industries reported exceeding 2024 financial results with $4.2 billion in Q4 revenue and $16.5 billion in full-year revenue; however, its share price fell almost 10% due to a less optimistic 2025 outlook of $16.8-17.4 billion in revenue and $2.35-2.65 non-GAAP EPS.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What were the key financial results of Teva Pharmaceuticals in 2024, and how did the market react to the 2025 outlook?

Teva Pharmaceutical Industries exceeded analysts' expectations for its 2024 fourth-quarter and full-year financial results, reporting $4.2 billion in Q4 revenue and $16.5 billion in full-year revenue, exceeding guidance. However, the company's share price dropped nearly 10% due to a less optimistic 2025 outlook.

forbes.com

🌐 85% Global Worthiness

Jul 10, 19:15

PBMs: The Primary Driver of High Drug Prices

The FTC and DOJ listening sessions revealed that Pharmacy Benefit Managers (PBMs), not pharmaceutical companies, are the primary cause of high drug prices due to their anti-competitive practices; the three largest PBMs control 80% of prescriptions, favoring higher-priced drugs and limiting access to...

PBMs: The Primary Driver of High Drug Prices

The FTC and DOJ listening sessions revealed that Pharmacy Benefit Managers (PBMs), not pharmaceutical companies, are the primary cause of high drug prices due to their anti-competitive practices; the three largest PBMs control 80% of prescriptions, favoring higher-priced drugs and limiting access to...

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do PBMs' practices hinder the development and market entry of generic and biosimilar drugs?

PBMs' actions stifle competition and innovation, particularly impacting biosimilars. Their rebate structure incentivizes the selection of higher-priced drugs, even when cheaper options exist, resulting in reduced market share for biosimilars and a decline in new biosimilar development. This is further compounded by PBMs' control over formularies and the use of prior authorization and "fail-first" requirements.

forbes.com

🌐 85% Global Worthiness

Apr 18, 01:15

Trump EO Seeks Systemic Solutions to High Prescription Drug Costs

President Trump's April 15th executive order directs officials to find solutions to high prescription drug prices by addressing misaligned incentives, PBM practices, and site-neutral payments within 180 days.

Trump EO Seeks Systemic Solutions to High Prescription Drug Costs

President Trump's April 15th executive order directs officials to find solutions to high prescription drug prices by addressing misaligned incentives, PBM practices, and site-neutral payments within 180 days.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate, specific actions the Trump administration will take to reduce prescription drug costs for American consumers?

On April 15th, President Trump issued an executive order (EO) aiming to lower prescription drug prices. The EO directs various officials to propose solutions within 180 days for long-standing issues, including misaligned incentives and high costs compared to other countries.

jpost.com

🌐 75% Global Worthiness

Feb 19, 01:08

Teva's Market Cap Falls $6 Billion Despite Positive 2024 Results

Teva Pharmaceutical Industries' market cap fell by roughly $6 billion to $18.8 billion after its 2025 profit guidance disappointed investors despite positive 2024 results that exceeded expectations, prompting CEO Richard Francis to highlight the company's growth strategy focusing on branded drugs.

Teva's Market Cap Falls $6 Billion Despite Positive 2024 Results

Teva Pharmaceutical Industries' market cap fell by roughly $6 billion to $18.8 billion after its 2025 profit guidance disappointed investors despite positive 2024 results that exceeded expectations, prompting CEO Richard Francis to highlight the company's growth strategy focusing on branded drugs.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate consequences of Teva's disappointing 2025 profit guidance on its market capitalization and investor sentiment?

Teva Pharmaceutical Industries saw its market cap decline by approximately $6 billion to $18.8 billion following the release of its positive 2024 financial results. While exceeding analyst forecasts, the company's 2025 profit guidance disappointed investors, triggering a negative market reaction. CEO Richard Francis attributes this to evolving expectations for Teva, signifying a shift from concerns about survival to expectations of further growth.

Showing 1 to 7 of 7 results